Výsledky vyhledávání

Akademický článek

Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines

Autor: Julia eEschenbrenner, Sebastian eWinsel, Stefanie eHammer, Anette eSommer, Kevin eMittelstaedt, Michael eDrosch, Ulrich eKlar, Christoph eSachse, Michael eHannus, Monika eSeidel, Bertram eWeiss, Claudia eMerz, Gerhard eSiemeister, Jens eHoffmann

Publikováno v: Frontiers in Oncology, Vol 1 (2011)

The molecular heterogeneity of cancer calls for individualized therapies to become the standard of care. The development of new therapeutic agents needs to include integrative translational research as early as possible. Target-specific compounds req

Externí odkaz: https://doaj.org/article/abcee1644460400a8419ea530ac3eee4

Zobrazit plný text záznamu

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group

Autor: H. Wiesinger, Ulrich Bogdahn, Jacoline E C Bromberg, Alicia Tosoni, J.M.M. Gijtenbeek, Peter Hau, W.T.A. van der Graaf, Anouk Allgeier, Denis Lacombe, Marc Frenay, Mario Campone, Alba A. Brandes, Roger Stupp, Hwan Jung Yun, M. J. van den Bent, L. Breimer, Thierry Gorlia

Publikováno v: Annals of Oncology, 22, 2144-9
Annals of Oncology, 22, 9, pp. 2144-9
Annals of Oncology, vol. 22, no. 9, pp. 2144-2149
Annals of Oncology
Annals of Oncology, 22(9), 2144-2149. Elsevier Ltd.

Item does not contain fulltext BACKGROUND: Sagopilone (ZK 219477), a lipophylic and synthetic analog of epothilone B, that crosses the blood-brain barrier has demonstrated preclinical activity in glioma models. PATIENTS AND METHODS: Patients with fir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aff761ff942a5427a762451d3bee2780
http://doc.rero.ch/record/291521/files/mdq729.pdf

Zobrazit plný text záznamu

Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

Autor: David Smith, Y. Wang, K. Roth, A. Hussain, M. Giurescu, Tomasz M. Beer, Jue Wang, M. Alonso

Publikováno v: British Journal of Cancer

Background: Preclinical studies in prostate cancer (PC) models demonstrated the anti-tumour activity of the first fully synthetic epothilone, sagopilone. This is the first study to investigate the activity and safety of sagopilone in patients with me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00908c7f696a11d24ab91f96d93e8987
https://doi.org/10.1038/bjc.2012.339

Zobrazit plný text záznamu

Novel Drugs Targeting Microtubules: the Role of Epothilones

Autor: Gabriella Ferrandina, Giovanni Scambia, Cristiano Ferlini, Shohreh Shahabi, Mirko Andreoli, Marisa Mariani

Publikováno v: Current Pharmaceutical Design. 18:2793-2803

Among the drugs targeting microtubule functions by interfering with tubulin subunits, epothilones represent a class of anticancer agents which recently entered clinical development. Although epothilones share mechanisms of action similar to taxanes,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::633baaa25ea307cc9958fdae70df9fd2
https://doi.org/10.2174/138161212800626238

Zobrazit plný text záznamu

Asymmetric Total Synthesis of the Epothilone Sagopilone - From Research to Development

Autor: Ulrich Klar, Johannes Platzek

Publikováno v: Synlett. 23:1291-1299

We describe our successful efforts for the translation of our research strategy that was focused on a broad structural modification of the natural product epothilone B, to the production of the distinct drug candidate sagopilone in a kg scale. By a d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51cbf80ef96cb973e52b8d9f14fe75f6
https://doi.org/10.1055/s-0031-1290163

Zobrazit plný text záznamu

First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors

Autor: Toru Mukohara, Kazuhiro Araki, Keiji Kodama, Kiyomi Mera, Hirofumi Mukai, Yuichi Ando, Masaru Narabayashi, Yasutsuna Sasaki, Koichi Kitagawa, Hironobu Minami

Publikováno v: Investigational New Drugs. 30:2327-2333

Purpose Sagopilone has recently been identified and preferentially used for the treatment of taxane-resistant cancer. The purpose of this dose-escalation study was to investigate the safety, tolerability, and pharmacokinetics (PK) of sagopilone in re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd9cbd5b49f1a5de9073397944b4d7ca
https://doi.org/10.1007/s10637-011-9773-7

Zobrazit plný text záznamu

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer

Autor: J Burke, Claire F. Verschraegen, P Celano, Y. Wang, T Schmelter, S McMeekin, M Giurescu, Prafull Ghatage, Steven C. Plaxe, C Stredder, R Patel

Publikováno v: British Journal of Cancer

Background: Sagopilone is the first fully synthetic epothilone in clinical development and has demonstrated promising preclinical activity. This phase I/II, prospective, open-label trial investigated the efficacy and safety of sagopilone plus carbopl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74cef51b3cf4e7ed69ca033d1ca52c8c
http://europepmc.org/articles/PMC3251849

Zobrazit plný text záznamu

Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial

Autor: H.-J. Schmoll, Wieland Voigt, S. Lindemann, H. Wiesinger, S. Reif, C. Behrmann, Philipp Kiewe, Eckhard Thiel, M. Giurescu, Dirk Arnold

Publikováno v: British Journal of Cancer

Background: Epothilones are a novel class of microtubule-stabilising agents, and sagopilone is a fully synthetic epothilone that has shown marked in vivo and in vitro preclinical activity. Methods: This phase I, open-label study investigated the maxi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b56db85b788adabee4d3206caa45b95
https://doi.org/10.1038/sj.bjc.6605327

Zobrazit plný text záznamu

The Epothilones: How Pharmacology Relates to Clinical Utility

Autor: Laura Boehnke Michaud

Publikováno v: Annals of Pharmacotherapy. 43:1294-1309

Objective: To review the pharmacologic properties of a novel class of chemotherapeutic agents, the epothilones, and to summarize findings from recent clinical trials investigating the various epothilones in cancer therapy. Data Sources: Literature se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::796587b41854521da7f2c3d1e0bd7ef3
https://doi.org/10.1345/aph.1m005

Zobrazit plný text záznamu

Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate

Autor: Jens Hoffmann, Marius Giurescu, Ulrich Klar

Publikováno v: Expert Opinion on Investigational Drugs. 17:1735-1748

Tubulin is among the most established and clinically validated targets in oncology. The taxanes, paclitaxel and docetaxel, stabilize microtubules and have shown significant clinical activity, but factors such as the development of resistance can limi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d900f6e9b4e1010e784da5afb206669c
https://doi.org/10.1517/13543784.17.11.1735

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání